Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices (NASDAQ: MASS) has announced the launch of a new downloadable target pack for its MX908 mass spectrometry device, enabling rapid identification of toxic pesticides. Developed with the U.S. Forest Service, this upgrade allows for quick on-site detection, empowering first responders to act promptly against hazardous chemicals implicated in illegal marijuana cultivation. The MX908 can now identify eight dangerous pesticides, providing crucial intelligence for environmental safety and public health.
908 Devices Inc. (Nasdaq: MASS), a leader in handheld and desktop mass spectrometry devices, will participate in two investor conferences in location value="LU/us.ny.nyc"New York, NY. The events include a Fireside Chat at the Stifel 2022 Healthcare Conference on November 16 at 1:15 p.m. Eastern Time, and a Fireside Chat at the Canaccord Genuity MedTech Forum on November 17 at 10:00 a.m. Eastern Time. Investors can access live and archived webcasts on the company's website.
908 Devices Inc. (NASDAQ: MASS) will release its financial results for Q3 2022 on November 14, 2022, before market opening. A conference call is scheduled for 5:30 a.m. PT / 8:30 a.m. ET, which will be available via webcast on the company's website. 908 Devices specializes in handheld and desktop mass spectrometry devices designed for chemical and biomolecular analysis, catering to critical applications in life sciences, pharma, and forensics. The company is based in Boston and focuses on democratizing mass spectrometry technology.
908 Devices (NASDAQ: MASS) announced a successful collaboration with CPI, demonstrating their REBEL™ device's ability to enhance cell growth in bioprocessing. Using the REBEL, CPI optimized nutrient levels for a monoclonal antibody-producing cell line, achieving up to a 40% increase in titer while controlling toxic metabolite accumulation. The REBEL provides real-time data tracking, facilitating informed decisions on feeding strategies and improving both efficiency and product quality.
908 Devices Inc. (NASDAQ: MASS) reported Q2 2022 revenue of $11.1 million, a 34% increase year-over-year, driven by strong sales in handheld and desktop devices, with desktop revenue growing 39%. The company achieved a gross margin of 60% compared to 53% in the same quarter last year. Despite a net loss of $8.1 million, cash reserves stood at $213 million. Looking ahead, 908 Devices expects 2022 revenue between $52 million and $55 million, indicating 23% to 30% growth from 2021.
908 Devices (NASDAQ: MASS) has completed its acquisition of TRACE Analytics GmbH, a German firm specializing in online analysis and sampling systems for biotech applications. The purchase includes an initial payment of $15.3 million, plus up to $2.0 million contingent on future milestones. This acquisition aims to enhance 908 Devices' mass spec devices for on-line bioprocess monitoring, aligning with their goal of developing a comprehensive bioanalytics platform. The integration is expected to bolster their capabilities in providing actionable insights for Bioprocessing 4.0.
908 Devices Inc. (Nasdaq: MASS) will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, hosting a Fireside Chat at 2:00 p.m. Eastern Time. The event aims to communicate the company's innovations in mass spectrometry technology, addressing critical applications in life sciences, pharma, and more. Interested parties can access the live and archived webcast via the company's website.
908 Devices is headquartered in Boston and focuses on democratizing laboratory technology with its handheld and desktop devices.
908 Devices Inc. (NASDAQ: MASS) will report its second quarter 2022 financial results on August 9, 2022, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET, accessible via the company's website. As a leader in handheld and desktop mass spectrometry devices, 908 Devices aims to improve accessibility to critical analytical technology in various sectors, including life sciences and forensics. Investors can expect insights into the company’s performance and future outlook during this upcoming event.
908 Devices (NASDAQ: MASS) is presenting its handheld and desktop mass spectrometry technologies at the 70th ASMS Conference from June 5-9 in Minneapolis. The company emphasizes the accessibility of mass spec for researchers, showcasing the ZipChip device and its application in drug development. Key presentations include collaborations with Boehringer Ingelheim and Genentech, focusing on oligonucleotides and proteomics. The conference highlights 12 presentations, comprising one oral and eleven posters, aimed at enhancing drug development workflows.
908 Devices Inc. (NASDAQ: MASS) will participate in the William Blair 42nd Annual Growth Stock Conference on June 9th at 8:00 a.m. Central Time. Interested parties can access a live and archived webcast on the company’s website. 908 Devices specializes in handheld and desktop mass spectrometry devices aimed at addressing critical applications in life sciences, pharma, and forensics. The company is headquartered in Boston and focuses on innovative solutions that provide quick analysis of unknown materials.